Human Biomarkers and Therapeutics in MS Research
The revised McDonald criteria enhance MS diagnosis using biomarkers like CSF KFLC index and serum NfL. Fluid biomarkers show potential for tracking inflammation and treatment response, but require standardization. The treatment options for progressive MS have expanded with several new therapies at various developmental stages.
- Tags
- #Biomarkers
- Most relevant to
- —
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
These advancements could lead to earlier diagnoses and improved treatment strategies for MS, particularly progressive forms that lack effective therapies.
What this does not prove
Assay standardization and validation of biomarkers are necessary before they can be routinely used in clinical settings, and results are still pending.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Other
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-07
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Biomarkers, Other
Original sources
- Primary evidenceMultiple sclerosis: Advances in diagnosis, biomarkers, and disease management. ↗DOI: 10.1016/j.jneuroim.2026.579106
Supporting passages (6)
study designThis review summarizes these developments and considers how convergent progress in diagnostics, biomarkers, and mechanistically diverse therapies is changing the approach to disability accrual in MS, and what obstacles remain.
subjectsIn parallel, fluid biomarkers-particularly serum neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP)-together with high-throughput CSF proteomics are showing promise as tools for detecting inflammatory activity, smoldering neuroinflammation, and treatment response, although assay standardization and prospective validation are still needed before most are ready for routine clinical use.
research categoriesThis review summarizes these developments and considers how convergent progress in diagnostics, biomarkers, and mechanistically diverse therapies is changing the approach to disability accrual in MS, and what obstacles remain.
publication date2026-10-07
findingsThe therapeutic pipeline has expanded beyond relapsing disease toward the unmet need of progressive MS, with extended anti-CD20 strategies, Bruton's tyrosine kinase (BTK) inhibitors, CD40 ligand (CD40L) blockade, vidofludimus calcium, and chimeric antigen receptor (CAR) T-cell therapies at varying stages of clinical development, from late-phase trials to early proof-of-concept studies, alongside renewed efforts in remyelination and repair.
limitationsIn parallel, fluid biomarkers-particularly serum neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP)-together with high-throughput CSF proteomics are showing promise as tools for detecting inflammatory activity, smoldering neuroinflammation, and treatment response, although assay standardization and prospective validation are still needed before most are ready for routine clinical use.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.